CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Pentostatin Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2026-08-27. Latest FDA row update: 2026-08-27.
FDA lists 1 package records, with companies: Hospira, Inc., Hospira, Inc., a Pfizer Company. Package NDCs: 0409-0801-01.
FDA shortage reason: Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Hospira, Inc., a Pfizer Company | 0409-0801-01 | Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01) | Unavailable | 2026-08-27 |
Source facts
Grouped generic ingredient: Pentostatin Injection · 1 package records
Therapeutic categories: Oncology
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-11T19:09:08+00:00. Derived grouping is documented in this record's derivations.